Something doesn’t add up here.
There are times when you sit back scratch your head and wonder just what’s going on. The other day Insulet pays Bigfoot $25 million for their patent portfolio related to automated insulin dosing (AID). Which was a win win as it provides Bigfoot with desperately needed capital and strengthens Insulet’s patent position. Yet the irony here the head scratcher is what Abbott whose an investor in Bigfoot didn’t do.
Abbott CEO Robert Ford has been very vocal about Abbott’s quest for acquisitions that would help sell more Libre’s. The company recently signed a deal with . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.